Loading...
₹ 0
0.00%
Loading...
About
Loading... [1]
- Market Cap ₹ 0 Cr.
- Current Price ₹ 0
- High / Low ₹ 0 / 0
- Stock P/E
- Dividend Yield 0 %
- ROE 0 %
- EPS 0
- P/B Ratio 0
- Net Profit Margin 0 %
- Debt to Equity 0
- ROCE 0 %
- Interest Coverage 0 %
Stock News - Agul
Latest updates related to Agul
| Sr No. | Title | Sentiment |
|---|---|---|
| 1 | Venus Remedies gets Marketing Authorization for anticoagulant ‘Enoxaparin’ from Indonesia NewsPatrolling | 🔄 |
| 2 | Parthenolide improves sepsis-induced coagulopathy by inhibiting mitochondrial-mediated apoptosis in vascular endothelial cells through BRD4/BCL-xL pathway Journal of Translational Medicine | 🔄 |
| 3 | Ultraman Gaia and Agul Coming to Ultraman Orb the Origin Saga The Tokusatsu Network | 🔄 |
| 4 | Zero[Hz] uses upbeat synths to carry "AGUL" music video JROCK NEWS | 🔄 |
| 5 | Case Report: IVC-Agenesis and FVL Mutation; Successful DVT/PE Treatment with Direct Oral Anticoagulation (Factor Xa inhibitor) Frontiers | 🔄 |
| 6 | Glenmark Pharma edges higher after US launch of coagulation disorder drug Phytonadione Business Standard | 🔄 |
| 7 | Hikal ownership row: Company accuses Baba Kalyani of selectively leaking Vagul's letter The New Indian Express | 🔄 |
Loading peers table...
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Loading data...
Quarterly Data Visualization
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Loading Profit & Loss data...
Profit & Loss Data Visualization:
| Compounded Sales Growth | |
|---|---|
| 10 Years: | |
| 5 Years: | |
| 3 Years: | |
| TTM: | |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | |
| 5 Years: | |
| 3 Years: | |
| TTM: | |
| Stock Price CAGR | |
|---|---|
| 10 Years: | |
| 5 Years: | |
| 3 Years: | |
| 1 Year: | |
| Return on Equity | |
|---|---|
| 10 Years: | |
| 5 Years: | |
| 3 Years: | |
| Last Year: | |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Balance Sheet Data Visualization:
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Ratios
Consolidated Figures in Rs. Crores / View Standalone